Acurx Pharmaceuticals, Inc. (ACXP)
- Previous Close
2.0200 - Open
2.0400 - Bid 2.0500 x 100
- Ask 2.1200 x 100
- Day's Range
1.9850 - 2.0800 - 52 Week Range
1.1700 - 8.8200 - Volume
28,594 - Avg. Volume
99,434 - Market Cap (intraday)
32.617M - Beta (5Y Monthly) -1.90
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1500 - Earnings Date May 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.09
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
www.acurxpharma.comRecent News: ACXP
Performance Overview: ACXP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACXP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACXP
Valuation Measures
Market Cap
32.62M
Enterprise Value
25.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.72
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-106.65%
Return on Equity (ttm)
-243.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.58M
Diluted EPS (ttm)
-1.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
7.47M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.33M